1. Volume 60, Issue 5, Pages 920-927 (May 2014)
A randomized, double-blind, multiple-dose study of the pan-genotypic NS5A inhibitor samatasvir in patients infected with hepatitis C virus genotype 1, 2, 3 or 4 
Bradley Vince, John M. Hill, Eric J. Lawitz, William O’Riordan, Lynn R. Webster, Daniel M. Gruener, Ricky S. Mofsen, Abel Murillo, Eileen Donovan, Jie Chen, Joseph F. McCarville, John Z. Sullivan-Bólyai, Douglas Mayers, Xiao-Jian Zhou 
Journal of Hepatology 
Volume 60, Issue 5, Pages (May 2014)
DOI: /j.jhep
Copyright © 2014 European Association for the Study of the Liver Terms and Conditions

2. Fig. 1 Chemical structure of samatasvir.
Journal of Hepatology  , DOI: ( /j.jhep )
Copyright © 2014 European Association for the Study of the Liver Terms and Conditions

3. Fig. 2
Plasma HCV RNA, genotypes 1, 3 and 4. Mean (+ standard error) reduction from baseline in plasma HCV RNA in subjects with genotype 1, 3 or 4 HCV.
Journal of Hepatology  , DOI: ( /j.jhep )
Copyright © 2014 European Association for the Study of the Liver Terms and Conditions

4. Fig. 3
Plasma HCV RNA, genotypes 2. Individual and mean (+ standard error) reduction from baseline in plasma HCV RNA in subjects with genotype 2 HCV.
Journal of Hepatology  , DOI: ( /j.jhep )
Copyright © 2014 European Association for the Study of the Liver Terms and Conditions

5. Fig. 4
Pharmacokinetics. Mean (+ standard deviation) day-3 plasma pharmacokinetic profiles over 24h of samatasvir.
Journal of Hepatology  , DOI: ( /j.jhep )
Copyright © 2014 European Association for the Study of the Liver Terms and Conditions